KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $148.6 million.

  • Twist Bioscience's Cash & Equivalents fell 3288.26% to $148.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $148.6 million, marking a year-over-year decrease of 3288.26%. This contributed to the annual value of $183.0 million for FY2025, which is 1911.8% down from last year.
  • As of Q4 2025, Twist Bioscience's Cash & Equivalents stood at $148.6 million, which was down 3288.26% from $183.0 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Cash & Equivalents registered a high of $475.3 million during Q2 2021, and its lowest value of $148.6 million during Q4 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $276.4 million (2023), whereas its average is $293.0 million.
  • Examining YoY changes over the last 5 years, Twist Bioscience's Cash & Equivalents showed a top increase of 39732.46% in 2021 and a maximum decrease of 4506.02% in 2021.
  • Twist Bioscience's Cash & Equivalents (Quarter) stood at $191.6 million in 2021, then surged by 65.26% to $316.7 million in 2022, then fell by 15.92% to $266.3 million in 2023, then decreased by 16.85% to $221.4 million in 2024, then crashed by 32.88% to $148.6 million in 2025.
  • Its last three reported values are $148.6 million in Q4 2025, $183.0 million for Q3 2025, and $201.4 million during Q2 2025.